BridgeBio Pharma Inc.'s drug Attruby gained FDA approval to treat a rare heart disease, competing with Pfizer's medications. The drug's label claims to stabilize the misshapen transport protein linked to the disease, potentially challenging Pfizer's market dominance.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing